Exelixis Inc Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Exelixis Inc (EXEL) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $589.31 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-05
- 2026-07-03: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $589.31M.
- 2026-04-03: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $480.39M.
- 2026-01-02: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $58.20M.
- 2025-10-03: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $39.78M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-07-03 | $589.31M 10-Q · filed 2026-08-05 |
| 2026-04-03 | $480.39M 10-Q · filed 2026-05-05 |
| 2026-01-02 | $58.20M 10-Q · filed 2026-08-05 |
| 2025-10-03 | $39.78M 10-Q · filed 2025-11-04 |
| 2025-07-04 | $331.00M 10-Q · filed 2025-07-28 |
| 2025-04-04 | $292.88M 10-Q · filed 2025-05-13 |
| 2025-01-03 | $495.29M 10-K · filed 2026-02-10 |
| 2024-09-27 | $91.92M 10-Q · filed 2024-10-29 |
| 2024-06-28 | $459.86M 10-Q · filed 2024-08-06 |
| 2024-03-29 | $577.66M 10-Q · filed 2024-04-30 |
| 2023-12-29 | $419.30M 10-K · filed 2025-02-11 |
| 2022-12-30 | $793.19M 10-K · filed 2024-02-06 |
| 2020-01-03 | $17.38M 10-K · filed 2020-02-25 |
| 2019-09-27 | $119.81M 10-Q · filed 2019-10-30 |
| 2019-06-28 | $33.57M 10-Q · filed 2019-07-31 |
| 2019-03-29 | $49.23M 10-Q · filed 2019-05-01 |
| 2018-12-28 | $271.36M 10-K · filed 2020-02-25 |
| 2018-09-28 | $218.05M 10-Q · filed 2018-11-01 |
| 2017-12-29 | $154.36M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |